prevents epithelial cell apoptosis. 8, 9 The underlying stromal matrix contains proteins that suppress transforming growth factor (TGF)-β signaling in fibroblasts, and consequently inhibit the proliferation and differentiation into myofibroblasts, extracellular matrix production, and scar formation.
The resultant downregulation is responsible for the antifibrosis effect.
10-12
The anti-inflammatory activity of AM is attributed to numerous mediators, including interleukin (IL)-1 receptor antagonist, IL-10, activin, inhibin, and inter-α-trypsin inhibitor. 12-14 AM has also been shown to induce apoptosis of inflammatory cells. [14] [15] [16] [17] Vascularization is inhibited by the antiinflammatory effect of AM and by the antiangiogenic proteins present within AM, including endostatin, thrombospondin-1, and inhibitors of metallo-proteases. 13, 18 Finally, a unique advantage of AM is the low immunogenicity of the tissue and, therefore, the consequent lack of rejection. 4, [19] [20] [21] The immunosuppressive ability of AM to inhibit a mixed lymphocyte reaction appears to be partly mediated by a soluble factor, resulting in decreased alloreactive T-cell proliferation and Th1 and Th2 cytokine production. In the field of ocular surface reconstruction, the use of AMT in the surgical management of pterygium has gained popularity since the first utilization by Prabhasawat in 1997. 24 In addition to the surgical goals of successful removal of the pterygium and achieving an optimal postoperative cosmetic result, the primary concern for the surgeon is recurrence. The clinical results with AMT have been variable, with recurrence rates ranging from 3 to 41% 24-31 for primary pterygium and from 9.5 to 52.6% for recurrent pterygium. 24, 27, [30] [31] [32] [33] Although the rate of recurrence with AMT is much lower than with primary closure, the results compared with conjunctival autografting alone have not been consistent. [24] [25] [26] 28, 30, 31 More severe inflammation has been found to be related to higher rates of recurrence.
52,53
AM has been modified to broaden its utility. Minimal amounts of FG are recommended due to its potential pro-inflammatory effect. To address this concern a bio-adhesive-coated AMT (fibrinogen and thrombin) was created, maintaining the biological characteristics of AM and bypassing the need for sutures. 54 In addition to use as a graft, AM has been used as a temporary patch for the surgical treatment of primary treatment without recurrence (n=20). 55 In conjunction with a fixed AMT graft, a temporary AMT patch may be beneficial after pterygium surgery, similar to sutureless AMT for partial limbal stem cell deficiency. 56 AM is commercially available to be used as a temporary patch with Preserved Amniotic Membrane Transplantation for Ocular Surface Reconstruction
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